Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study

Figure 1

Kaplan-Meier estimate of progression-free survival. The plot depicts the probability of progression-free survival over time (months) for patients who received everolimus (full analysis set population). The square symbol represents censoring times. The number of patients still at risk is shown for each time point.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us